AUS
NZ
UK
CA
USA
IND
Highlights
- Immutep tested IMP761, a LAG-3 agonist, in a conceptual safety study involving 49 healthy participants.
- No adverse effects were reported, confirming the safety of the world’s first LAG-3 agonist antibody in its early testing phase.
- The study focused on safety and immunosuppressive efficacy, not effectiveness against autoimmune diseases or cancers.
Immutep Ltd (ASX:IMM) has reported encouraging safety results from a small-scale Phase I safety trial of its flagship drug IMP761. Despite no adverse effects being observed among 49 healthy participants, the company's shares dropped nearly 3% in early Tuesday trade, closing at 34 cents per share.
Details of the Study
IMP761 is a pioneering LAG-3 agonist antibody targeting immune system dysregulation. This drug seeks to address autoimmune conditions such as arthritis, diabetes, and multiple sclerosis (MS) by modulating antigen-specific T-cell activity.
The safety trial did not involve patients with autoimmune diseases but was conducted on healthy participants to evaluate safety and immune responses. This early-phase study is a critical step toward advancing the drug’s application in autoimmune diseases.
Dr. Frederic Triebel, Chief Scientific Officer at Immutep, expressed optimism about the findings:
“We are very encouraged by the safety data generated to date for IMP761, the world’s first LAG-3 agonist antibody, in this Phase I setting. Derisking this promising asset in this proof-of-concept study in healthy subjects assessing its safety and immunosuppressive efficacy is an important step for this exciting program in autoimmune diseases.”
Challenges with Investor Sentiment
Despite the positive safety outcomes, the trial’s data does not demonstrate the drug's effectiveness in treating autoimmune diseases or cancers, which may have dampened investor enthusiasm.
In the past, Immutep has explored IMP761's potential in cancer treatments, particularly for blood cancers with autoimmune characteristics. However, shareholders may be growing impatient, possibly due to a lack of significant progress or concrete efficacy data in these areas.
Outlook
The successful safety profile of IMP761 provides a strong foundation for future trials targeting autoimmune diseases. As the company transitions toward testing in patients with autoimmune conditions, further updates on the drug's efficacy will be closely watched by investors.
